Literature DB >> 24605270

Key sleep neurologic disorders: Narcolepsy, restless legs syndrome/Willis-Ekbom disease, and REM sleep behavior disorder.

Erik K St Louis1.   

Abstract

Sleep disorders are frequent comorbidities in neurologic patients. This review focuses on clinical aspects and prognosis of 3 neurologic sleep disorders: narcolepsy, restless legs syndrome/Willis-Ekbom disease (RLS/WED), and REM sleep behavior disorder (RBD). Narcolepsy causes pervasive, enduring excessive daytime sleepiness, adversely affecting patients' daily functioning. RLS/WED is characterized by an uncomfortable urge to move the legs before sleep, often evolving toward augmentation and resulting in daylong bothersome symptoms. RBD causes potentially injurious dream enactment behaviors that often signify future evolution of overt synucleinopathy neurodegeneration in as many as 81% of patients. Timely recognition, referral for polysomnography, and longitudinal follow-up of narcolepsy, RLS/WED, and RBD patients are imperatives for neurologists in providing quality comprehensive patient care.

Entities:  

Year:  2014        PMID: 24605270      PMCID: PMC3943657          DOI: 10.1212/01.CPJ.0000442523.60659.02

Source DB:  PubMed          Journal:  Neurol Clin Pract        ISSN: 2163-0402


  20 in total

Review 1.  Iron for restless legs syndrome.

Authors:  Lynn M Trotti; Srinivas Bhadriraju; Lorne A Becker
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

2.  Is rapid eye movement sleep behavior disorder in Parkinson disease a specific disease subtype?

Authors:  Stuart J McCarter; Erik K St Louis; Bradley F Boeve
Journal:  Sleep Med       Date:  2013-08-29       Impact factor: 3.492

3.  Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study.

Authors:  Wolfgang Oertel; Claudia Trenkwalder; Heike Beneš; Luigi Ferini-Strambi; Birgit Högl; Werner Poewe; Karin Stiasny-Kolster; Andreas Fichtner; Erwin Schollmayer; Ralf Kohnen; Diego García-Borreguero
Journal:  Lancet Neurol       Date:  2011-06-24       Impact factor: 44.182

4.  Restless legs syndrome and daytime sleepiness are prominent in myotonic dystrophy type 2.

Authors:  Erek M Lam; Paul W Shepard; Erik K St Louis; Lucas G Dueffert; Nancy Slocumb; Stuart J McCarter; Michael H Silber; Bradley F Boeve; Eric J Olson; Virend K Somers; Margherita Milone
Journal:  Neurology       Date:  2013-06-07       Impact factor: 9.910

5.  Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study.

Authors:  Jason R Cornelius; Maja Tippmann-Peikert; Nancy L Slocumb; Courtney F Frerichs; Michael H Silber
Journal:  Sleep       Date:  2010-01       Impact factor: 5.849

6.  Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder.

Authors:  B F Boeve; M H Silber; T J Ferman; S C Lin; E E Benarroch; A M Schmeichel; J E Ahlskog; R J Caselli; S Jacobson; M Sabbagh; C Adler; B Woodruff; T G Beach; A Iranzo; E Gelpi; J Santamaria; E Tolosa; C Singer; D C Mash; C Luca; I Arnulf; C Duyckaerts; C H Schenck; M W Mahowald; Y Dauvilliers; N R Graff-Radford; Z K Wszolek; J E Parisi; B Dugger; M E Murray; D W Dickson
Journal:  Sleep Med       Date:  2013-03-07       Impact factor: 3.492

7.  Treatment outcomes in REM sleep behavior disorder.

Authors:  Stuart J McCarter; Christopher L Boswell; Erik K St Louis; Lucas G Dueffert; Nancy Slocumb; Bradley F Boeve; Michael H Silber; Eric J Olson; Maja Tippmann-Peikert
Journal:  Sleep Med       Date:  2013-01-23       Impact factor: 3.492

8.  Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study.

Authors:  Alex Iranzo; Eduard Tolosa; Ellen Gelpi; José Luis Molinuevo; Francesc Valldeoriola; Mónica Serradell; Raquel Sanchez-Valle; Isabel Vilaseca; Francisco Lomeña; Dolores Vilas; Albert Lladó; Carles Gaig; Joan Santamaria
Journal:  Lancet Neurol       Date:  2013-04-03       Impact factor: 44.182

9.  Nocturnal rapid eye movement sleep latency for identifying patients with narcolepsy/hypocretin deficiency.

Authors:  Olivier Andlauer; Hyatt Moore; Laura Jouhier; Christopher Drake; Paul E Peppard; Fang Han; Seung-Chul Hong; Francesca Poli; Giuseppe Plazzi; Ruth O'Hara; Emmanuel Haffen; Thomas Roth; Terry Young; Emmanuel Mignot
Journal:  JAMA Neurol       Date:  2013-07       Impact factor: 18.302

10.  Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy--a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group.

Authors:  C H Schenck; J Y Montplaisir; B Frauscher; B Hogl; J-F Gagnon; R Postuma; K Sonka; P Jennum; M Partinen; I Arnulf; V Cochen de Cock; Y Dauvilliers; P-H Luppi; A Heidbreder; G Mayer; F Sixel-Döring; C Trenkwalder; M Unger; P Young; Y K Wing; L Ferini-Strambi; R Ferri; G Plazzi; M Zucconi; Y Inoue; A Iranzo; J Santamaria; C Bassetti; J C Möller; B F Boeve; Y Y Lai; M Pavlova; C Saper; P Schmidt; J M Siegel; C Singer; E St Louis; A Videnovic; W Oertel
Journal:  Sleep Med       Date:  2013-07-22       Impact factor: 4.842

View more
  1 in total

Review 1.  Profile of pitolisant in the management of narcolepsy: design, development, and place in therapy.

Authors:  Andrea Romigi; Giuseppe Vitrani; Temistocle Lo Giudice; Diego Centonze; Valentina Franco
Journal:  Drug Des Devel Ther       Date:  2018-08-30       Impact factor: 4.162

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.